The US biotech firm Catabasis Pharmaceuticals has named Rick Modi as its new chief business officer.
Modi brings to Catabasis 15 years of experience in corporate, business and product commercialisation strategy.
Jill Milne, co-founder and chief executive of Catabasis, said: “Rick has valuable experience across multiple brands, including orphan drug positioning, commercialisation and marketing.
“We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”
Modi added: “Catabasis has a novel approach to drug development that allows for simultaneous modulation of multiple targets in a disease pathway, and I am privileged to join this team as we seek to bring disease-modifying treatments to patients with DMD or severe lipid disorders.”
Prior to joining Catabasis, Modi was senior vice president, global marketing at InterMune – an orphan drug company that was acquired by Roche late last year.
He played a large role in the launch of InterMune’s flagship product, the lung-scarring drug Esbriet (pirfenidone).
Modi has also held roles of increasing responsibilities in corporate strategy, new product planning and sales and marketing at AstraZeneca’s biologics arm MedImmune as well as J&J’s subsidiary Centocor.